GlassScriptPhysician profile
Shahryar Mafi
NPI 1750338505
$14,254.66
in general payments reported to CMS, 2019-2025
41 companies · $2,509 in 2025
The $2,509 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,811 · 2020: $424 · 2021: $1,240 · 2022: $2,566 · 2023: $2,696 · 2024: $3,009 · 2025: $2,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,197 · Education: $17.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,196.97 |
| Education | $17.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,137.21 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,138.12 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $1,111.79 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $1,019.39 | 2019-2024 | Jot Dx, Aveir, Mitraclip |
| Cvrx, INC. | $885.76 | 2021-2025 | Barostim Neo System |
| Amgen INC. | $664.96 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $646.93 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $645.19 | 2021-2025 | Verquvo, Capvaxive |
| Scpharmaceuticals INC. | $625.65 | 2023-2025 | |
| Esperion Therapeutics, INC. | $607.74 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $559.72 | 2021-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $490.45 | 2019-2025 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $456.38 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $399.45 | 2020-2025 | Farxiga |
| Edwards Lifesciences Corporation | $391.21 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $247.79 | 2024 | |
| Amarin Pharma, INC. | $233.47 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.40 | 2022-2025 | Jardiance |
| Bridgebio Pharma, INC. | $170.86 | 2025 | Attruby |
| Medtronic, INC. | $166.77 | 2025 | Linq II |
| Bayer Healthcare Pharmaceuticals INC. | $163.69 | 2022-2025 | |
| Kestra Medical Technology Services, INC. | $161.33 | 2023-2024 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $153.85 | 2019-2025 | Evkeeza |
| Atricure, INC. | $134.46 | 2022 | |
| Sanofi-Aventis U.S. LLC | $126.86 | 2019-2023 | |
| Medtronic Vascular, INC. | $125.00 | 2020 | |
| Cardiovascular Systems INC. | $120.96 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $56.18 | 2019-2022 | |
| Philips North America LLC | $49.62 | 2020 | |
| Baxter Healthcare | $48.87 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Gilead Sciences, INC. | $45.19 | 2019 | |
| Chiesi USA, INC. | $41.04 | 2024-2025 | Juxtapid |
| Amryt Pharma Holdings LTD | $31.25 | 2023 | Juxtapid |
| Recor Medical INC | $28.00 | 2025 | Paradise Ultrasound Renal Denervation System |
| Abiomed | $23.84 | 2024 | |
| Astellas Pharma US INC | $22.92 | 2020 | |
| Azurity Pharmaceuticals, INC. | $22.54 | 2024 | Edarbi |
| Lexicon Pharmaceuticals, INC. | $20.78 | 2023 | Inpefa |
| Qorumpartners | $20.59 | 2022 | |
| Coala Life INC | $18.12 | 2021 | |
| Medicomp INC | $14.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahryar Mafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.